ARTICLE | Deals
Zai breaks into neuroscience with Karuna deal, adds cancer asset from Blueprint
Cross-border company lays out $60M in pair of deals
November 10, 2021 12:05 AM UTC
With a pair of new territorial licensing deals, Zai is bringing one asset in a familiar therapeutic area, and another in an entirely new one.
Prolific licensing company Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) said Tuesday it had made its first foray into neurology by adding rights in Greater China to a schizophrenia therapy from Karuna Therapeutics Inc. (NASDAQ:KRTX) that has entered pivotal testing...